Damage control in rheumatoid arthritis: Hard-hitting, early treatment is crucial to curbing joint destruction

Postgraduate Medicine

Volumn 116, Issue 5, 2004, Pages

  Issa, Sakeba N ^a   Ruderman, Eric M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; HYDROXYCHLOROQUINE SULFATE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RHEUMATREX DOSE PACK; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VITAMIN D;

BONE DENSITY; CATARACT; CLINICAL FEATURE; CONFERENCE PAPER; COST OF ILLNESS; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL ASSESSMENT; HAND RADIOGRAPHY; HUMAN; HYPERTENSION; JOINT DESTRUCTION; JOINT STIFFNESS; KINESIOTHERAPY; LABORATORY TEST; MEDICAL DECISION MAKING; MORNING STIFFNESS; OCCUPATIONAL THERAPY; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICAL CAPACITY; PHYSIOTHERAPY; PREVENTIVE MEDICINE; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; RISK ASSESSMENT; SIDE EFFECT; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

EID: 19644401161     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2004.11.1608     Document Type: Conference Paper

References (30)

1. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiol Rev 1981;3:27-44
2. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24
3. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33(3):305-15
4. Goronzy J, Weyand C. Rheumatoid arthritis: epidemiology, pathology, and pathogenesis. In: Klippel JH, Crofford LJ, Stone J, et al, eds. Primer on the rheumatic diseases. 12th ed. Atlanta: Arthritis Foundation, 2001:209-17
5. Fleming A, Crown JM, Corbett M. Early rheumatoid disease. I. Onset. Ann Rheum Dis 1976;35(4):357-60
6. Fleming A, Benn RT, Corbett M, et al. Early rheumatoid disease. II. Patterns of joint involvement. Ann Rheum Dis 1976;35(4):361-4
7. Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J 1973;2(5858):96-100
8. Edworthy SM. Morning stiffness: Sharpening an old saw? J Rheumatol 1999;26(5):1015-7
9. 4 pp 218-24
10. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62(9):870-4
11. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101(1):273-81
12. Bas S, Genevay S, Meyer O, et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003;42(5):677-80
13. Solomon DH, Kavanaugh AJ, Schur PH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47(4):434-44
14. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35(1):26-34
15. Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16(5):585-91
16. Klarlund M, Ostergaard M, Jensen KE, et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis 2000;59(7):521-8
17. Terslev L, Torp-Pedersen S, Savnik A, et al. Doppler ultrasound and magnetic resonance imaging of synovial inflammation of the hand in rheumatoid arthritis: a comparative study. Arthritis Rheum 2003;48(9):2434-41
18. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46(2):328-46
19. Furst DE, Keystone EC, Breedveld FC, et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis 2001; 60(Suppl 3):iii2-5
20. Lipsky PE, van der Heijde DM, St Clair EW, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343(22):1594-602
21. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130(6):478-86
22. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343(22):1586-93 [Errata, N Engl J Med 2001;344(3):240 and N Engl J Med 2001;344(1):76]
23. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343(22):1586-93 [Errata, N Engl J Med 2001;344(3):240 and N Engl J Med 2001;344(1):76]
24. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343(22):1586-93 [Errata, N Engl J Med 2001;344(3):240 and N Engl J Med 2001;344(1):76]
25. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46(6):1443-50
26. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002;61(Suppl 2):ii70-3
27. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46(3):614-24
28. Klareskog L, van der Heijde D, de Jager JP, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363(9410):675-81
29. Hakkinen A, Sokka T, Kotaniemi A, et al. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum 2001;44(3):515-22
30. Schiaffino KM, Revenson TA, Gibofsky A. Assessing the impact of self-efficacy beliefs on adaptation to rheumatoid arthritis. Arthritis Care Res 1991;4(4):150-7